Unlocking the potential of allogeneic Vδ2 T cells for ovarian cancer therapy through CD16 biomarker selection and CAR/IL-15 engineering
We employed CD16 as a biomarker to identify and select Vδ2 T cell PBMC donors. CD16 high Vδ2 T cells were then engineered with a Mesothelin-targeted chimeric antigen receptor and soluble IL-15 for the treatment of ovarian cancers
Microscopic sequences of synthetic polymers are critical to polymer properties, but are generally unavailable from traditional characterizations. Here, we achieved imaging of single synthetic polymers with single-monomer resolution and sequencing of synthetic copolymers for the first time.